< Back to previous page
Researcher
Johan Vansteenkiste
- Disciplines:Respiratory medicine
Affiliations
- Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE) (Division)
Member
From1 Oct 1999 → 30 Sep 2022
Projects
1 - 3 of 3
- Refining the role of dual checkpoint inhibition in advanced lung cancer: a single-cell approachFrom5 Oct 2021 → TodayFunding: FWO Strategic Basic Research Grant
- A single-cell approach to identify biomarkers of efficacy and toxicity for immune checkpoint blockade in non-small cell lung cancer.From1 Aug 2019 → 1 Aug 2023Funding: FWO Strategic Basic Research Grant, Foundations, funds and other with scientific goal
- Unraveling the common genetic basis for COPD, emphysema and lung cancer.From1 Aug 2010 → 16 Dec 2015Funding: Private funding of national origin - undefined, FWO fellowships
Publications
21 - 30 of 278
- Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(2021)
Authors: Johan Vansteenkiste
Pages: 839 - 853 - Osimertinib in patients with advanced/metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer-the Belgian ASTRIS data(2021)
Authors: Johan Vansteenkiste
Pages: 224 - 231 - Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial(2021)
Authors: Johan Vansteenkiste
Pages: 860 - 867 - Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial(2021)
Authors: Johan Vansteenkiste
Pages: 92 - 98 - Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14)(2021)
Authors: Maarten Lambrecht, Johan Vansteenkiste
Pages: 278 - 288 - Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer(2020)
Authors: Johan Vansteenkiste
Pages: 944 - 957 - Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study(2020)
Authors: Johan Vansteenkiste
Pages: 137 - 142 - Capmatinib in patients with METex14-mutated advanced non-small cell lung cancer who received prior immunotherapy: The phase II GEOMETRY mono-1 study(2020)
Authors: Johan Vansteenkiste, EF Smit, HJM Groen, EB Garon, RS Heist, T Hida, M Nishio, K Kokowski, C Grohe, N Reguart, et al.
Pages: S830 - S830 - A microsimulation model to assess the impact of SARS-CoV-2 on cancer outcomes, healthcare organization and economic burden(2020)
Authors: P Van Mol, A Franken, C Dooms, Jonas Yserbyt, Dries Testelmans, P Meersseman, G Hermans, J Wauters, J Gunst, Kristiaan Nackaerts, et al.
Pages: S1207 - S1207 - Keeping exhausted T-cells in check in COVID-19(2020)
Authors: P Van Mol, A Franken, C Dooms, Jonas Yserbyt, Dries Testelmans, P Meersseman, G Hermans, J Wauters, J Gunst, Kristiaan Nackaerts, et al.
Pages: S1208 - S1208